Anti-inflammation drug may also cut risk of heart disease and cancer: study
New York
A DRUG that fights inflammation can reduce the risk of heart attacks and strokes, and possibly lung cancer, in people who have already had one heart attack and are at high risk for another, a new study finds.
Researchers outside the study say the findings represent a major milestone - proof of a biologic concept that opens the door to new ways of treating and preventing cardiovascular disease in people who are still at risk despite standard therapies.
"This is fantastic," said Dr David J Maron, director of preventive cardiology at Stanford University School of Medicine. "The green light just went on for full-fledged investigation and development of effective and cost-effective new therapies."
But experts also cautioned that potentially fatal side effects of the drug, as well as its high cost, mean it is unlikely to be widely used.
Cardiovascular disease is the leading cause of death worldwide and in the United States, where it killed nearly 634,000 people in 2015. Globally, it killed 15 million.
The drug that was studied, canakinumab, is already marketed under the brand name Ilaris, but was approved to treat a type of juvenile rheumatoid arthritis and other rare disorders, not heart disease. It costs about US$200,000 a year and is made by Novartis, which paid for the new study. The company declined to say whether the price would change if the drug came into more general use for heart disease.
The drug works differently from the cholesterol-lowering statin medicines that have become mainstays in treating and preventing heart disease. Unlike statins, it has no effect on cholesterol. Instead, it reduces inflammation - the response by the immune system to injury or infection - which researchers have long suspected of playing a role in cardiovascular disease and cancer. About half of people who have heart attacks have normal cholesterol levels, and researchers think that in some of them, inflammation may contribute to heart and artery disease.
But because the drug suppresses part of the immune system, it increases the risk of infections, including fatal ones.
Deaths from infection in the study appeared to match lives saved by the drug, so there was no difference in overall mortality between the groups that got the drug and the placebo.
An editorial by Dr Robert A Harrington of Stanford University in The New England Journal of Medicine, which published the cardiovascular results of the study on Sunday, described the cardiovascular benefit as "modest", called for more information about the fatal infections and said the drug was too expensive to be used in such a common disease.
Dr Eric Peterson, a cardiologist and director of the Duke Clinical Research Institute at Duke University, also said he thought the drug would not be widely used, but added: "There might be ways to develop other drugs that could be safer and cheaper to lower inflammation." NYTIMES
TRENDING NOW
Motoring tycoon Peter Kwee is back in court: Here are his previous legal battles
Peter Kwee’s Ridley Park bungalow on the market with S$100 million asking price
Demand, tech capabilities position Apac and AI as Skyscanner’s next growth frontiers: CEO Bryan Batista
South-east Asia has lost Nvidia’s best salesman